While the market continues its fervent chase after hot tech stocks, contrarian investors are turning their attention to a sector full of contrast and opportunity: biotech companies that have fallen out of favor temporarily but possess solid long-term futures.
Following the 2025 stock price adjustments, a significant divergence has emerged between the fundamentals and the share prices of Viking Therapeutics (VKTX) and BioNTech (BNTX)—companies with deep pipelines in weight-loss medication and cancer vaccines, respectively. This disconnect presents a notable window for long-term investors.
This pronounced divergence is no accident. It reflects both the market’s overreaction to short-term earnings volatility and signals that companies with genuine technological moats and clear catalytic pathways are entering a unique phase where “negative expectations are fully digested, but long-term value remains unpriced.”
In the red ocean of the GLP-1 weight-loss drug market, dominated by industry giants, Viking Therapeutics is carving out a niche with notable competitive differentiation through its core candidate, VK2735. Currently in Phase 3 trials, VK2735’s mid-stage clinical data has demonstrated potential for superior efficacy and safety profiles compared to many competitors’ candidates at similar stages, forming the company’s most solid foothold in the fierce competition.
The company’s strategy reveals long-term vision and a clear roadmap. Beyond advancing the subcutaneous formulation, Viking is simultaneously developing an oral version of VK2735, directly addressing the core patient need for convenience. More crucially, the company is not stopping at initial weight loss but is delving deeper into optimizing dosing regimens to help patients maintain weight long-term—a research direction precisely targeting a key unmet need in the current market.
Furthermore, Viking plans to initiate clinical trials for a novel weight-management candidate in 2026, continuously enriching its pipeline. The market widely anticipates that while critical Phase 3 data for VK2735 may not arrive until 2027, progress in other pipeline assets and formulations throughout 2026 could serve as significant catalysts for the stock.
The market’s perception of BioNTech is in urgent need of an update—it is far from a mere “post-pandemic” story. Instead, it is an innovator systematically pivoting its proven mRNA technology platform towards the field of oncology therapeutics. As revenue from its COVID-19 vaccine normalizes, the success of its transformation hinges on its robust oncology pipeline. 2026 is poised to be a pivotal year for validating this transformation, with several important clinical readouts expected.
Among these, the late-stage candidate BNT113 for head and neck cancer, which has received FDA Fast Track designation, is slated for an interim analysis from its ongoing late-stage trial this year. Concurrently, interim data for the Phase 3 candidate Trastuzumab Pamirtecan, targeting endometrial cancer, is also anticipated within the year.
BioNTech’s diversified portfolio of oncology candidates ensures a steady stream of clinical progress, providing long-term support for the stock price. These clinical milestones mean BioNTech’s shares could experience multiple data-driven re-rating opportunities in 2026. The core of its long-term investment thesis lies in validating the efficacy and commercial viability of mRNA technology in oncology, thereby decisively moving beyond reliance on a single COVID product.
Investing in biotechnology is fundamentally about finding certainty within uncertainty. Short-term stock prices swing violently driven by sentiment, capital flows, and clinical events, whereas long-term value is ultimately determined by the efficacy of the technology platform and the delivery of its pipeline.
Both Viking and BioNTech are currently in a similar phase: the market has cooled on them due to short-term performance or sector cycles, while their respective technological paths are approaching critical validation points within the next 12-24 months. This very contrast between “short-term uncertainty” and “long-term clear prospects” constitutes the risk-reward opportunity contrarian investors seek.
